By John Carroll Scientific American recently selected the top five countries in the world for their ability to foster biotechnology based on a few key criteria, and the results may surprise you. The magazine focused on intellectual property and the ability to protect IP; biotech “intensity,” which includes R&D spending; enterprise support, including the availability …
By Tracy Staton Think Pfizer (NYSE: PFE) has had enough of buyouts for awhile, now that it’s partially digested the $68 billion Wyeth acquisition? Think again. CFO Frank D’Amelio told the German newspaper Handelsblatt that the company is scouting for potential buys in several specific areas, including emerging markets. Pfizer’s also interested in acquisitions that would augment …
By Liz Jones Scotland is looking to keep life sciences jobs in the country, even as Merck MSD says it will have to close a site in Newhouse by the end of the year. Finance Secretary John Swinney recently met with officials from the company to explore how to protect employment in Newhouse, and officials at …
By Maureen Martino Amgen (NASDAQ: AMGN) has about $20 billion on hand to finance new deals. But while the U.S. and Europe are the biggest markets, CEO Kevin Sharer says his company will be looking for deals in emerging markets due to the greater potential for growth there. “We seek good companies at a fair …
By Liz Jones Teva Pharmaceutical Industries (NASDAQ: TEVA) sees chances to grow in Latin America, including such major markets as Brazil and Mexico. Eyal Desheh, Teva’s CFO, said the company doesn’t have the right presence in Brazil right now, and it should be able to get bigger in Mexico. He made these comments Thursday at the …
By John Carroll A new study in Nature Biotechnology explores the rapidly proliferating links among developers in the Southern Hemisphere as they push for new therapies, vaccines and diagnostic tests that will specifically help the world’s poorest people in developing nations. Researchers from five developing nations joined with Canada’s McLaughlin-Rotman Centre for Global Health to track …
By Tracey Staton Analysts were cheering Roche today as the Swiss drugmaker posted a 6 percent rise in first-quarter revenues, beating estimates. The company also confirmed its forecasts for the year, with CEO Severin Schwan saying that his company is “fully on track for 2010.” First-quarter sales came in at $11.64 billion. In a way, …
